Global leader in hip replacement releases new offerings in clinical portfolio, addressing primary to complex revision arthroplasty
Echo Bi-Metric Microplasty Stem
The Echo Bi-Metric Microplasty stem is a metaphyseal loading, fit-and-fill femoral prosthesis implanted through a simple, broach-only surgical technique. Based on the clinically proven Bi-Metric family of hip prostheses1, the Echo Bi-Metric Microplasty stem is approximately 30 percent shorter than the full-length Echo Bi-Metric stem, conserving more of the patient's natural bone and enabling the use of minimally invasive surgical approaches.
G7 Dual Mobility Construct
The G7 Dual Mobility Construct offers surgeons the benefit of dislocation resistance without the need to constrain the femoral head, combining stability and high range of motion for a variety of patient indications.2,3 The addition of the G7 Dual Mobility Construct expands
Zimmer Biomet's comprehensive portfolio of shell, fixation and bearing options within the G7 Acetabular System, which enable surgeons to personalize implant selection and establish a stable joint in total hip arthroplasty. The G7 Acetabular System also offers clinicians and healthcare systems the benefits of a streamlined instrumentation and delivery platform.
Arcos One-Piece Femoral Revision System
The Arcos One-Piece Femoral Revision system offers three fully porous, titanium stem options with a unique range of sizes that can address small femora. The Arcos One-Piece System builds on the clinical success of the Arcos Modular System4 launched in 2010, and offers the same popular stem geometry, intuitive instrumentation and straightforward surgical technique.
"The Zimmer Biomet Hip portfolio is the most comprehensive on the market, and these exciting product introductions represent our strength and commitment to expanding our offerings through our passion and dedication to efficient product development and launch," said
Jim Lancaster, Vice President & General Manager of the global hip business. "The healthcare environment is rapidly changing, and we remain focused on the timely introduction of clinically relevant, cost-effective solutions that meet the individual needs of patients, surgeons and hospitals around the world."
About Zimmer Biomet
Founded in 1927 and headquartered in
Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.
We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.
We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit zimmerbiomet.com or follow
Zimmer Biomet on Twitter at twitter.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "aims," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," and "seeks" or the negatives of such terms or other variations on such terms or comparable terminology. Forward-looking statements include, but are not limited to, statements concerning products and services offered by
Zimmer Biomet, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see our periodic reports filed with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Accordingly, such forward-looking statements speak only as of the date made. Readers of this communication are cautioned not to place undue reliance on these forward-looking statements, since, while management believes the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this communication.
1. Meding, J. et al. Twenty-year Follow-up of an Uncemented Stem in Primary THA. Clinical Orthopaedics and Related Research. (473): 543-8, 2014.
2. Active Articulation Hip Bearings. IFU 01-50-1254 Rev B.
3. Pietrzak, W. Dual-Mobility Acetabular Components: Design Rationale for Enhanced Stability. Biomet Orthopedics Form No. BOI0480.0 REV033111.
4. Frye, B. et al. Modular Femoral Tapered Revision Stems in Total Hip Arthroplasty. Joint Implant Surgery & Research Foundation. 3(3): 31-7, 2013.
Published at ZimmerBiomet Investor Relation